Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Stott

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Nursing Times|November 5, 2008
Changing treatments for overactive bladderElizabeth Waine, Mark Stott
BJU International|September 2, 2020
Percutaneous microwave ablation of renal masses in a UK cohortJoseph B John, Moira Anderson, Thomas Dutton, et al.
Journal of the National Cancer Institute|May 17, 2007
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)Malcolm D Mason, Matthew R Sydes, John Glaholm, et al.
Journal of the National Cancer Institute|September 4, 2003
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)David P Dearnaley, Matthew R Sydes, Malcolm D Mason, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Nursing Times|November 5, 2008
Changing treatments for overactive bladderElizabeth Waine, Mark Stott
BJU International|September 2, 2020
Percutaneous microwave ablation of renal masses in a UK cohortJoseph B John, Moira Anderson, Thomas Dutton, et al.
Journal of the National Cancer Institute|May 17, 2007
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)Malcolm D Mason, Matthew R Sydes, John Glaholm, et al.
Journal of the National Cancer Institute|September 4, 2003
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)David P Dearnaley, Matthew R Sydes, Malcolm D Mason, et al.
Pageof 1